You are here

Clinical Laserthermia Systems to Exhibit MRI-Guided Laser Thermal Therapy System at 12th Interventional MRI Symposium

Minimally Invasive, Non-Cooled Laser Fiber Eliminates External Cooling & Helps Reduce Procedure Times

FRAMINGHAM, Mass., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS Americas), a subsidiary of CLS AB in Lund, Sweden, today announced it will be exhibiting its TRANBERG® | Thermal Therapy System and single-use accessories at the 12th Interventional MRI Symposium this October 5-6, 2018 in Boston, Massachusetts. The symposium will feature lectures by medical experts, scientific presentations, and technical exhibits by vendors.

CLS developed its TRANBERG® |Thermal Therapy System as a minimally invasive, safe solution for MRI-guided focal laser ablation treatments for tumors and soft tissue.  Its unique, non-cooled, laser fiber technology is designed to optimize heat distribution, eliminate the need for external cooling, and help reduce procedure times.

“CLS is excited to present our Thermal Therapy System and products at this year’s annual Interventional MRI Symposium,” stated Alan Weinberg, General Manager for CLS Americas, Inc. “Participants and attendees for this symposium are precisely the types of experts, physicians, and clinicians our medical instruments and products are designed for.” 

In the United States alone, new prostate cancer cases for 2017 were estimated at 161,360 and deaths at 26,730 according to the AACR. Focal therapies for low risk and intermediate risk localized prostate cancer are increasingly being explored. 

About the CLS TRANBERG® | Thermal Therapy System
CLS developed the system for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for MR or CT/US-guided procedures using tissue temperature feedback for precise therapy and ablation control. The system includes a desktop mobile laser unit, new innovative non-cooled laser applicators, external tissue temperature probe sensors and procedure specific accessories.

About Clinical Laserthermia Systems
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG® | Thermal Therapy System and specially-designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Boston, MA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on www.clinicallaser.se.

The TRANBERG® |Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) by the Food and Drug Administration (FDA) in the United States of America (USA).

CONTACT: Media Contact
TopSpin Communications
Joe Waldygo
P: 480-363-8774
E: joe@topspinpr.com

Company Contact
CLS Americas, Inc.
Alan Weinberg, General Manager 
P: 508-620-4521
E: alan@clinicallaser.se
Thursday, October 4, 2018 - 07:00